Advanced type 2 diabetes mellitus is associated with significant morbidity and mortality due to cardiovascular, nervous, and renal complications. Attempts to cure diabetes mellitus using islet transplantation have been successful in providing a source for insulin secreting cells. However, limited donors, graft rejection, the need for continued immune suppression, and exhaustion of the donor cell pool prompted the search for a more sustained source of insulin secreting cells. Stem cell therapy is a promising alternative for islet transplantation in type 2 diabetic patients who fail to control hyperglycemia even with insulin injection. Autologous stem cell transplantation may provide the best outcome for those patients, since autologous cells are readily available and do not entail prolonged hospital stays or sustained immunotoxic therapy. Among autologous adult stem cells, mesenchymal stem cells (MSCs) therapy has been applied with varying degrees of success in both animal models and in clinical trials. This review will focus on the advantages of MSCs over other types of stem cells and the possible mechanisms by which MSCs transplant restores normoglycemia in type 2 diabetic patients. Sources of MSCs including autologous cells from diabetic patients and the use of various differentiation protocols in relation to best transplant outcome will be discussed. 1. Introduction Obesity and diabetes are the major health challenges for the twenty first century, according to a recent report by the International Diabetes Foundation. The connection between obesity and diabetes is evident in sharing the same risk factors and the fact that 80–90% of type 2 diabetics are also obese. Diabetes is one of the top ten leading causes of death worldwide, according to a recent WHO report [1]. The global prevalence of diabetes in 2012 was estimated to be more than 10% among adults. Of the diabetic population 95% are of type 2, and onset is mainly at an adult age (more than 25 years), with the highest prevalence in the Eastern Mediterranean region and the Americas. Diabetes is the leading cause of renal failure and blindness in advanced countries, and the risk of limb amputation is 10 times higher in diabetic patients. In addition, most diabetic patients develop hypertension and cardiovascular diseases, which account for high rates of morbidity and mortality among adult patients. The disease can be initially treated by oral medication, but eventually, some 27% become insulin dependent. Of these, less than one half achieve the recommended HB A1c level [2], since exogenous insulin
References
[1]
WHO Report, “Burden: mortality, morbidity and risk factors—WHO report,” Global Status Report on NCDs, 2010.
[2]
C. E. Koro, S. J. Bowlin, N. Bourgeois, and D. O. Fedder, “Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report,” Diabetes Care, vol. 27, no. 1, pp. 17–20, 2004.
[3]
A. M. J. Shapiro, J. R. T. Lakey, E. A. Ryan et al., “Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen,” The New England Journal of Medicine, vol. 343, no. 4, pp. 230–238, 2000.
[4]
E. A. Ryan, B. W. Paty, P. A. Senior et al., “Five-year follow-up after clinical islet transplantation,” Diabetes, vol. 54, no. 7, pp. 2060–2069, 2005.
[5]
M. D. Bellin, F. B. Barton, A. Heitman et al., “Potent induction immunotherapy promotes long-term insulin independence after islet transplantation in type 1 diabetes,” American Journal of Transplantation, vol. 12, no. 6, pp. 1576–1583, 2012.
[6]
N. Lumelsky, O. Blondel, P. Laeng, I. Velasco, R. Ravin, and R. McKay, “Differentiation of embryonic stem cells to insulin-secreting structures similar to pancreatic islets,” Science, vol. 292, no. 5520, pp. 1389–1394, 2001.
[7]
Y. Jiang, B. N. Jahagirdar, R. L. Reinhardt et al., “Pluripotency of mesenchymal stem cells derived from adult marrow,” Nature, vol. 418, no. 6893, pp. 41–49, 2002.
[8]
E. Kroon, L. A. Martinson, K. Kadoya et al., “Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo,” Nature Biotechnology, vol. 26, no. 4, pp. 443–452, 2008.
[9]
W. Jiang, Y. Shi, D. Zhao, et al., “In vitro derivation of functional insulin-producing cells from human embryonic stem cells,” Cell Research, vol. 17, pp. 333–344, 2007.
[10]
K. Jeon, H. Lim, J. H. Kim, et al., “Differentiation and transplantation of functional pancreatic beta cells generated from induced pluripotent stem cells derived from a type 1 diabetes mouse model,” Stem Cells Development, vol. 21, no. 14, pp. 2642–2655, 2012.
[11]
E. Sivan-Loukianova, O. A. Awad, V. Stepanovic, J. Bickenbach, and G. C. Schatteman, “CD34+ blood cells accelerate vascularization and healing of diabetic mouse skin wounds,” Journal of Vascular Research, vol. 40, no. 4, pp. 368–377, 2003.
[12]
R. K. Burt, Y. Oyama, A. Traynor, and N. S. Kenyon, “Hematopoietic stem cell therapy for type 1 diabetes: induction of tolerance and islet cell neogenesis,” Autoimmunity Reviews, vol. 1, no. 3, pp. 133–138, 2002.
[13]
A. Bhansali, V. Upreti, N. Khandelwal et al., “Efficacy of autologous bone marrow-derived stem cell transplantation in patients with type 2 diabetes mellitus,” Stem Cells and Development, vol. 18, no. 10, pp. 1407–1415, 2009.
[14]
M. Zalzman, S. Gupta, R. K. Giri et al., “Reversal of hyperglycemia in mice by using human expandable insulin-producing cells differentiated from fetal liver progenitor cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 12, pp. 7253–7258, 2003.
[15]
I. Banakh, L. J. Gonez, R. M. Sutherland, G. Naselli, and L. C. Harrison, “Adult pancreas side population cells expand after β cell injury and are a source of insulin-secreting cells,” PLoS ONE, vol. 7, no. 11, Article ID E48977, 2012.
[16]
M. M. Gabr, M. M. Zakaria, A. F. Refaie et al., “Insulin-producing cells from adult human bone marrow mesenchymal stem cells control streptozotocin-induced diabetes in nude mice,” Cell Transplant, vol. 22, no. 1, pp. 133–145, 2013.
[17]
Y. Sun, L. Chen, X. G. Hou et al., “Differentiation of bone marrow-derived mesenchymal stem cells from diabetic patients into insulin-producing cells in vitro,” Chinese Medical Journal, vol. 120, no. 9, pp. 771–776, 2007.
[18]
O. Karnieli, Y. Izhar-Prato, S. Bulvik, and S. Efrat, “Generation of insulin-producing cells from human bone marrow mesenchymal stem cells by genetic manipulation,” Stem Cells, vol. 25, no. 11, pp. 2837–2844, 2007.
[19]
K. Timper, D. Seboek, M. Eberhardt et al., “Human adipose tissue-derived mesenchymal stem cells differentiate into insulin, somatostatin, and glucagon expressing cells,” Biochemical and Biophysical Research Communications, vol. 341, no. 4, pp. 1135–1140, 2006.
[20]
H. S. Wang, J. F. Shyu, W. S. Shen et al., “Transplantation of insulin-producing cells derived from umbilical cord stromal mesenchymal stem cells to treat NOD mice,” Cell Transplantation, vol. 20, no. 3, pp. 455–466, 2011.
[21]
K. Prabakar, J. Dominguez-Bendala, R. D. Molano, et al., “Generation of glucose-responsive, insulin-producing cells from human umbilical cord blood-derived mesenchymal stem cells,” Cell Transplantation, vol. 21, pp. 1321–1339, 2012.
[22]
K. Tateishi, J. He, O. Taranova, G. Liang, A. C. D'Alessio, and Y. Zhang, “Generation of insulin-secreting islet-like clusters from human skin fibroblasts,” The Journal of Biological Chemistry, vol. 283, no. 46, pp. 31601–31607, 2008.
[23]
X. Santamaria, E. E. Massosa, Y. Feng, et al., “Derivation of insulin producing cells from human endometrial stromal stem cells and use in the treatment of marine diabetes,” Molecular Therapy, vol. 19, pp. 2065–2071, 2011.
[24]
T. Sapir, K. Shternhall, I. Meivar-Levy et al., “Cell-replacement therapy for diabetes: generating functional insulin-producing tissue from adult human liver cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 22, pp. 7964–7969, 2005.
[25]
M. F. Pittenger, A. M. Mackay, S. C. Beck et al., “Multilineage potential of adult human mesenchymal stem cells,” Science, vol. 284, no. 5411, pp. 143–147, 1999.
[26]
Y. Ding, A. Bushell, and K. J. Wood, “Mesenchymal stem-cell immunosuppressive capabilities: therapeutic implications in islet transplantation,” Transplantation, vol. 89, no. 3, pp. 270–273, 2010.
[27]
N. S. El-Badri, B. Y. Wang, Cherry, and R. A. Good, “Osteoblasts promote engraftment of allogeneic hematopoietic stem cells,” Experimental Hematology, vol. 26, no. 2, pp. 110–116, 1998.
[28]
R. A. Cahill, O. Y. Jones, M. Klemperer et al., “Replacement of recipient stromal/mesenchymal cells after bone marrow transplantation using bone fragments and cultured osteoblast-like cells,” Biology of Blood and Marrow Transplantation, vol. 10, no. 10, pp. 709–717, 2004.
[29]
A. Y. Khakoo, S. Pati, S. A. Anderson et al., “Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma,” Journal of Experimental Medicine, vol. 203, no. 5, pp. 1235–1247, 2006.
[30]
R. S. Y. Wong, “Extrinsic factors involved in the differentiation of stem cells into insulin-producing cells: an over view,” Experimental Diabetes Research, vol. 2011, Article ID 406182, 15 pages, 2011.
[31]
J. Rajagopal, W. J. Anderson, S. Kume, O. I. Martinez, and D. A. Melton, “Development: insulin staining of ES cell progeny from insulin uptake,” Science, vol. 299, no. 5605, p. 363, 2003.
[32]
R. Calne and M. A. Ghoneim, “Novel diabetes therapy: the seven pillars of credibility. Treatment Strategies Diabetes,” www.treatmentstrategies.co.uk.
[33]
K. S. Choi, J. S. Shin, J. J. Lee, Y. S. Kim, S. B. Kim, and C. W. Kim, “In vitro trans-differentiation of rat mesenchymal cells into insulin-producing cells by rat pancreatic extract,” Biochemical and Biophysical Research Communications, vol. 330, no. 4, pp. 1299–1305, 2005.
[34]
H. Jahr and R. G. Bretzel, “Insulin-positive cells in vitro generated from rat bone marrow stromal cells,” Transplantation Proceedings, vol. 35, no. 6, pp. 2140–2141, 2003.
[35]
S. H. Oh, T. M. Muzzonigro, S. H. Bae, J. M. LaPlante, H. M. Hatch, and B. E. Petersen, “Adult bone marrow-derived cells trans differentiating into insulin-producing cells for the treatment of type I diabetes,” Laboratory Investigation, vol. 84, no. 5, pp. 607–617, 2004.
[36]
L. Y. Sun, H. Y. Zhang, X. B. Feng, Y. Y. Hou, L. W. Lu, and L. M. Fan, “Abnormality of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus,” Lupus, vol. 16, no. 2, pp. 121–128, 2007.
[37]
C. Moriscot, F. De Fraipont, M. J. Richard et al., “Human bone marrow mesenchymal stem cells can express insulin and key transcription factors of the endocrine pancreas developmental pathway upon genetic and/or microenvironmental manipulation in vitro,” Stem Cells, vol. 23, no. 4, pp. 594–603, 2005.
[38]
K. Okita, M. Nakagawa, H. Hyenjong, T. Ichisaka, and S. Yamanaka, “Generation of mouse induced pluripotent stem cells without viral vectors,” Science, vol. 322, no. 5903, pp. 949–953, 2008.
[39]
D. Marappagounder, I. Somasundaram, S. Dorairaj, and R. J. Sankaran, “Differentiation of mesenchymal stem cells derived from human bone marrow and subcutaneous adipose tissue into pancreatic islet-like clusters in vitro,” Cellular & Molecular Biology Letters, vol. 18, no. 1, pp. 75–88, 2013.
[40]
S. M. Phadnis, M. V. Joglekar, M. P. Dalvi et al., “Human bone marrow-derived mesenchymal cells differentiate and mature into endocrine pancreatic lineage in vivo,” Cytotherapy, vol. 13, no. 3, pp. 279–293, 2011.
[41]
B. Soria, A. Skoudy, and F. Martin, “From stem cells to beta cells: new strategies in cell therapy of diabetes mellitus,” Diabetologia, vol. 44, no. 4, pp. 407–415, 2001.
[42]
K. A. D'Amour, A. G. Bang, S. Eliazer et al., “Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells,” Nature Biotechnology, vol. 24, no. 11, pp. 1392–1401, 2006.
[43]
O. D. Madsen and P. Serup, “Towards cell therapy for diabetes,” Nature Biotechnology, vol. 24, no. 12, pp. 1481–1483, 2006.
[44]
H. A. Russ, E. Sintov, L. Anker-Kitai, et al., “Insulin-producing cells generated from dedifferentiated human pancreatic beta cells expanded in vitro,” PLoS ONE, vol. 6, no. 9, Article ID e25566.
[45]
J. Taneera, A. Rosengren, E. Renstrom et al., “Failure of transplanted bone marrow cells to adopt a pancreatic β-cell fate,” Diabetes, vol. 55, no. 2, pp. 290–296, 2006.
[46]
H. Okura, H. Komoda, Y. Fumimoto et al., “Transdifferentiation of human adipose tissue-derived stromal cells into insulin-producing clusters,” Journal of Artificial Organs, vol. 12, no. 2, pp. 123–130, 2009.
[47]
A. Pessina, B. Eletti, C. Croera, N. Savalli, C. Diodovich, and L. Gribaldo, “Pancreas developing markers expressed on human mononucleated umbilical cord blood cells,” Biochemical and Biophysical Research Communications, vol. 323, no. 1, pp. 315–322, 2004.
[48]
F. Gao, D. Q. Wu, Y. H. Hu, and G. X. Jin, “Extracellular matrix gel is necessary for in vitro cultivation of insulin producing cells from human umbilical cord blood derived mesenchymal stem cells,” Chinese Medical Journal, vol. 121, no. 9, pp. 811–818, 2008.
[49]
F. Gao, D. Q. Wu, Y. H. Hu et al., “In vitro cultivation of islet-like cell clusters from human umbilical cord blood-derived mesenchymal stem cells,” Translational Research, vol. 151, no. 6, pp. 293–302, 2008.
[50]
H. Kajiyama, T. S. Hamazaki, M. Tokuhara et al., “Pdx1-transfected adipose tissue-derived stem cells differentiate into insulin-producing cells in vivo and reduce hyperglycemia in diabetic mice,” International Journal of Developmental Biology, vol. 54, no. 4, pp. 699–705, 2010.
[51]
Y. Li, R. Zhang, H. Qiao et al., “Generation of insulin-producing cells from PDX-1 gene-modified human mesenchymal stem cells,” Journal of Cellular Physiology, vol. 211, no. 1, pp. 36–44, 2007.
[52]
S. Bonner-Weir, D. Deery, J. L. Leahy, and G. C. Weir, “Compensatory growth of pancreatic β-cells in adult rats after short-term glucose infusion,” Diabetes, vol. 38, no. 1, pp. 49–53, 1989.
[53]
L. Shin and D. A. Peterson, “Impaired therapeutic capacity of autologous stem cells in a model of type e diabetes,” Stem Cell Translational Medicine, vol. 1, pp. 125–135, 2012.
[54]
D. L. Deskins, D. Bastakoty, S. Sarawati, A. Shinar, G. E. Holt, and P. P. Young, “Human mesenchymal stromal cells: identifying assays to predict potency for therapeutic selection,” Stem Cell Translational Medicine, vol. 2, pp. 151–158, 2013.
[55]
N. S. El-Badri, A. Hakki, A. Ferrari, R. Shamekh, and R. A. Good, “Autoimmune disease: is it a disorder of the microenvironment?” Immunologic Research, vol. 41, no. 1, pp. 79–86, 2008.
[56]
N. Wijesekara, M. Krishnamurthy, A. Bhattacharjee, A. Suhail, G. Sweeney, and M. B. Wheeler, “Adiponectin-induced ERK and Akt phosphorylation protects against pancreatic beta cell apoptosis and increases insulin gene expression and secretion,” The Journal of Biological Chemistry, vol. 285, no. 44, pp. 33623–33631, 2010.
[57]
T. Y. Yeung, K. L. Seeberger, T. Kin et al., “Human mesenchymal stem cells protect human islets from pro-inflammatory cytokines,” PLoS One, vol. 7, no. 5, 2012.
[58]
F. E. Ezquer, M. E. Ezquer, D. B. Parrau, D. Carpio, A. J. Ya?ez, and P. A. Conget, “Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice,” Biology of Blood and Marrow Transplantation, vol. 14, no. 6, pp. 631–640, 2008.
[59]
F. Djouad, P. Plence, C. Bony et al., “Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals,” Blood, vol. 102, no. 10, pp. 3837–3844, 2003.
[60]
F. Djouad, C. Bony, F. Apparailly, P. Louis-Plence, C. Jorgensen, and D. No?l, “Earlier onset of syngeneic tumors in the presence of mesenchymal stem cells,” Transplantation, vol. 82, no. 8, pp. 1060–1066, 2006.
[61]
J. Tolar, A. J. Nauta, M. J. Osborn et al., “Sarcoma derived from cultured mesenchymal stem cells,” Stem Cells, vol. 25, no. 2, pp. 371–379, 2007.
[62]
S. Merani, C. Toso, J. Emamaullee, and A. M. J. Shapiro, “Optimal implantation site for pancreatic islet transplantation,” British Journal of Surgery, vol. 95, no. 12, pp. 1449–1461, 2008.
[63]
A. Rajab, “Islet transplantation: alternative sites,” Current Diabetes Reports, vol. 10, no. 5, pp. 332–337, 2010.
[64]
G. Christoffersson, J. Henriksn?s, L. Johansson et al., “Clinical and experimental pancreatic islet transplantation to striated muscle: establishment of a vascular system similar to that in native islets,” Diabetes, vol. 59, no. 10, pp. 2569–2578, 2010.
[65]
B. M. Prior, H. T. Yang, and R. L. Terjung, “What makes vessels grow with exercise training?” Journal of Applied Physiology, vol. 97, no. 3, pp. 1119–1128, 2004.
[66]
J. Svensson, J. Lau, M. Sandberg, and P. O. Carlsson, “High vascular density and oxygenation of pancreatic islets transplanted in clusters into striated muscle,” Cell Transplantation, vol. 20, no. 5, pp. 783–788, 2011.
[67]
A. O'Loughlin, M. Kulkarni, M. Creane et al., “Topical administration of allogenic mesenchymal stem cells seeded in a collagen scaffold augments wound healing and increases angiogenesis in the diabetic rabbit ulcer,” Diabetes. In press.
[68]
M. E. Ezquer, F. E. Ezquer, M. L. Arango-Rodrigues, and P. A. Conget, “MSCs transplantation: a promising therapeutic strategy to manage the onset and progression of diabetic nephropathy,” Biological Research, vol. 45, pp. 289–296, 2012.
[69]
S. Wang, Y. Li, J. Zhao, J. Zhang, and Y. Huang, “Mesenchymal stem cells ameliorate podocyte injury and proteinuria in a type 1 diabetic nephropathy rat model,” Biology of Blood and Marrow Transplantation, vol. 19, pp. 538–546, 2013.
[70]
E. T. Guimaraes, G. D. Cruz, T. F. de Almeida, et al., “Transplantation of stem cells obtained from murine dental pulp improves pancreatic damage, renal function and painful diabetic neuropathy in diabetic type I mouse model,” Cell Transplant. In press.
[71]
H. Kim, J. J. Kim, and Y. S. Yoon, “Emerging therapy for diabetic neuropathy: cell therapy targeting vessels and nerves,” Endocrine, Metabolic & Immune Disorders-Drug Targets, vol. 12, pp. 168–178, 2012.